The rise of copyright’s blockbuster initially sparked a period of growth for the drug industry, but recent shifts present a complicated picture for those considering a stake. Generic versions are eroding revenue, and persistent patent challenges add more risk to the landscape. While some companies may still gain from complementary products, the … Read More